Press Release

Source: Swiss Medica, Inc.

O24 Fibromyalgia Featured on National Television Show 'Walgreens Health Corner'

Wednesday March 1, 8:49 am ET

TORONTO--(BUSINESS WIRE)--March 1, 2006--Swiss Medica, Inc. (OTCBB:SWME - News) is pleased to announce that O24 Fibromyalgia was recently prominently featured on a segment on Fibromyalgia that aired on the "Walgreens Heath Corner" TV show that airs every Sunday morning on the Lifetime Network across the United States. Lifetime Network is one the highest rated cable television networks in the United States.

Lynne Matallana, President of the National Fibromyalgia Association (NFA), was interviewed on Health Corner TV and O24 Fibromyalgia was highlighted as the first and only product to receive the NFA Seal of Approval.

To view the clip on Fibromyalgia, please visit: http://www.024zone.com/healthcorner

Swiss Medica's President Grant Johnson noted, "As the first clinically tested OTC product for Fibromyalgia available in pharmacies in North America, O24 Fibromyalgia is receiving rave reviews from both consumers and the medical community as a safe, quick and effective pain reliever for the pain symptoms related to Fibromyalgia."

The Fibromyalgia segment is expected to re-air on the Health Corner TV show.

O24 Fibromyalgia is available nationally in retailers in North America, including Rite Aid and Shoppers Drug Mart. Please visit http://www.o24zone.com/ for a store locator.

About Swiss Medica, Inc.

Swiss Medica commercializes clinically tested, patented natural products that relieve chronic ailments. We grow our brands through focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of safe, effective chronic ailment products that improve quality of lives. Please visit our websites at http://www.swissmedica.com/ ,www.O24zone.com and http://www.pmsescape.com/.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.

Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Swiss Medica, Inc. (OTC Bulletin Board:SWME - News)

Contact:

Swiss Medica, Inc.
Investor Relations Contact:
David Jones
(866) 485-4243
djones@swissmedica.com
OR
Fusion Communications
Media Contact:
Dean Mailey
(604) 218-6767
dean@fusioncom.ca